Scholar Rock Holding Corp (SRRK)
26.87
-0.63
(-2.29%)
USD |
NASDAQ |
Nov 15, 12:56
Scholar Rock Cash from Financing (Quarterly): -0.033M for June 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | -0.033M |
March 31, 2024 | 6.525M |
December 31, 2023 | 96.53M |
September 30, 2023 | 0.28M |
June 30, 2023 | 4.689M |
March 31, 2023 | 1.076M |
December 31, 2022 | -0.97M |
September 30, 2022 | -0.451M |
June 30, 2022 | 195.77M |
March 31, 2022 | 0.481M |
December 31, 2021 | 39.70M |
September 30, 2021 | 1.906M |
June 30, 2021 | 0.607M |
March 31, 2021 | 2.737M |
December 31, 2020 | 246.46M |
Date | Value |
---|---|
September 30, 2020 | 0.368M |
June 30, 2020 | 0.595M |
March 31, 2020 | 0.399M |
December 31, 2019 | 0.818M |
September 30, 2019 | 6.124M |
June 30, 2019 | 42.10M |
March 31, 2019 | -0.157M |
December 31, 2018 | 16.93M |
September 30, 2018 | -1.464M |
June 30, 2018 | 78.97M |
March 31, 2018 | -0.167M |
December 31, 2017 | 46.72M |
September 30, 2017 | -0.167M |
June 30, 2017 | 4.119M |
March 31, 2017 | -0.167M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.97M
Minimum
Dec 2022
246.46M
Maximum
Dec 2020
31.45M
Average
0.818M
Median
Dec 2019
Cash from Financing (Quarterly) Benchmarks
Cytokinetics Inc | 3.425M |
Regeneron Pharmaceuticals Inc | -634.00M |
Ocugen Inc | 0.045M |
Mirum Pharmaceuticals Inc | 7.291M |
NeuroBo Pharmaceuticals Inc | -0.676M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -49.20M |
Cash from Investing (Quarterly) | 50.62M |
Free Cash Flow | -168.65M |
Free Cash Flow Per Share (Quarterly) | -0.5084 |
Free Cash Flow Yield | -6.85% |